Nikkomycin Z—Ready to Meet the Promise?

Nikkomycin Z (NikZ) has fungicidal activity against some fungal species which currently requires patients to endure chronic therapy, sometimes for years. This review highlights reports of NikZ activity against fungal species for which current therapeutics are still inadequate, as a potential roadmap...

Full description

Bibliographic Details
Main Author: David J. Larwood
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Journal of Fungi
Subjects:
Online Access:https://www.mdpi.com/2309-608X/6/4/261
_version_ 1797549281339506688
author David J. Larwood
author_facet David J. Larwood
author_sort David J. Larwood
collection DOAJ
description Nikkomycin Z (NikZ) has fungicidal activity against some fungal species which currently requires patients to endure chronic therapy, sometimes for years. This review highlights reports of NikZ activity against fungal species for which current therapeutics are still inadequate, as a potential roadmap for continuing investigation. The possibility of faster and more complete clinical resolution by using NikZ has attracted scientific attention for decades. NikZ inhibits chitin structure formation, which is important for fungi, but not found in mammals. NikZ raised no safety concerns in a human Phase 1 trial or in extensive toxicology studies. NikZ showed strong clinical benefit in dogs with natural <i>Coccidioides</i> infection. NikZ has protected animals against fatal infections of <i>Candida albicans</i>. NikZ provides high protection in synergistic combination with several agent classes against <i>Candida</i> and <i>Aspergillus</i> species.
first_indexed 2024-03-10T15:12:27Z
format Article
id doaj.art-e48dd603f4884f1baff8f2b4e114b390
institution Directory Open Access Journal
issn 2309-608X
language English
last_indexed 2024-03-10T15:12:27Z
publishDate 2020-10-01
publisher MDPI AG
record_format Article
series Journal of Fungi
spelling doaj.art-e48dd603f4884f1baff8f2b4e114b3902023-11-20T19:14:51ZengMDPI AGJournal of Fungi2309-608X2020-10-016426110.3390/jof6040261Nikkomycin Z—Ready to Meet the Promise?David J. Larwood0Valley Fever Solutions, Tucson, AZ 85719, USANikkomycin Z (NikZ) has fungicidal activity against some fungal species which currently requires patients to endure chronic therapy, sometimes for years. This review highlights reports of NikZ activity against fungal species for which current therapeutics are still inadequate, as a potential roadmap for continuing investigation. The possibility of faster and more complete clinical resolution by using NikZ has attracted scientific attention for decades. NikZ inhibits chitin structure formation, which is important for fungi, but not found in mammals. NikZ raised no safety concerns in a human Phase 1 trial or in extensive toxicology studies. NikZ showed strong clinical benefit in dogs with natural <i>Coccidioides</i> infection. NikZ has protected animals against fatal infections of <i>Candida albicans</i>. NikZ provides high protection in synergistic combination with several agent classes against <i>Candida</i> and <i>Aspergillus</i> species.https://www.mdpi.com/2309-608X/6/4/261antifungalnikkomycin ZNikZcombination therapyendemic dimorphic fungiopportunistic fungi
spellingShingle David J. Larwood
Nikkomycin Z—Ready to Meet the Promise?
Journal of Fungi
antifungal
nikkomycin Z
NikZ
combination therapy
endemic dimorphic fungi
opportunistic fungi
title Nikkomycin Z—Ready to Meet the Promise?
title_full Nikkomycin Z—Ready to Meet the Promise?
title_fullStr Nikkomycin Z—Ready to Meet the Promise?
title_full_unstemmed Nikkomycin Z—Ready to Meet the Promise?
title_short Nikkomycin Z—Ready to Meet the Promise?
title_sort nikkomycin z ready to meet the promise
topic antifungal
nikkomycin Z
NikZ
combination therapy
endemic dimorphic fungi
opportunistic fungi
url https://www.mdpi.com/2309-608X/6/4/261
work_keys_str_mv AT davidjlarwood nikkomycinzreadytomeetthepromise